Investors

BERKELEY HEIGHTS, N.J., Dec. 1, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), will host an Analyst and Institutional Investor meeting on December 7, 2011 in New York City from 11:00 a.m. to 1:00 p.m. Eastern. During the meeting Cyclacel management will review the clinical development program for sapacitabine including the design of SEAMLESS, the Company's ongoing, registration-directed, Phase 3 trial being conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA).

The meeting will include a discussion of:

(i) the mechanism of action of sapacitabine and future approaches for clinical investigation, both as a single agent and in combinations;

(ii) front-line treatment alternatives for elderly patients with acute myeloid leukemia (AML) by expert hematologists; and

(iii) treatment alternatives for patients with non-small cell lung cancer (NSCLC) who progress on currently available therapies by a thoracic oncology expert. 

Presenters will include:

• Philip Bonomi, M.D., Professor of Medical Oncology and Director, Division of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, IL.
   
• David Claxton, M.D., Professor, Division of Hematology Oncology, Penn State College of Medicine, Penn State Hershey Cancer Institute, Hershey, PA.
   
• William Plunkett, Ph.D., Professor and Deputy Chair, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
   
• Karen Seiter, M.D., Professor and Director, Adult Leukemia Service, New York Medical College / Westchester Oncology Hematology Group, PC, Valhalla, NY.

Webcast / Telecast Information:

The event will be webcast and may also be accessed by telephone.

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com.

For accessing the event by telephone:

US/Canada telecast: (877) 493-9121/ international telecast: (973) 582-2750.

The telecast code is 32526199.

The webcast will be archived for 90 days.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), an orally-available, cell cycle modulating, nucleoside analogue, is in a Phase 3 trial being conducted under a SPA with the U.S. FDA for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia. Seliciclib (CYC202 or R-roscovitine), an orally-available, CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

© Copyright 2011 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn® and Xclair® are trademarks of Sinclair Pharma plc.

CONTACT: Cyclacel Pharmaceuticals, Inc.

         Investors/Media:

         Corey Sohmer

         (908) 517-7330

         csohmer@cyclacel.com